CClinicalTrials.gg
RecruitingNCT05723653Updated Apr 8, 2026

Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention

An interventional study of Social Network Support Intervention in HIV Seropositivity, sponsored by University of Chicago. Recruiting at 7 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by University of Chicago · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Study summary

The goal of this Hybrid Type I effectiveness-implementation trial is to test an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV aged 18-49.

Read the detailed description

This study is a Hybrid Type I effectiveness-implementation trial of an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression. The study will be conducted in Chicago, Illinois and Alabama, two high burden priority areas in the National Ending the HIV Epidemic Plan. Both retention in care and viral suppression are critical targets in ongoing efforts to eliminate HIV, as persons adherent to antiretrovirals are unlikely to transmit HIV, and retention in care allows for ongoing monitoring of viral load and the delivery of other important services, e.g., case management, mental health, and substance use treatment.

Most clinic-based strategies to improve Continuum of Care outcomes focus on newly created network members, e.g., support groups, peer navigators, or case managers. In contrast, we identify and activate organic Support Confidants (SC)-those people who can offer the types of social support that can help to navigate life's complexities, including the stressors of living with HIV. The intervention uses sociograms, highly engaging social network diagrams, to identify an ideally positioned Support Confidant. Once a Support Confidant is identified, the Index and their Support Confidant attend a single session, in-person intervention with a trained interventionist. The intervention uses the Information Motivation Behavioral Skills Model, Motivational Interviewing, and Cognitive Behavioral Theory to promote Continuum of Care-specific support in the Index-Support Confidant relationship.

This study will conduct a Hybrid Type I randomized controlled trial with N=600 participants living with HIV, who will be randomized to receive the intervention (n=300) or treatment as usual (n=300). In addition, 300 Support Confidants also will be enrolled. At 12-months post-intervention, we will re-randomize dyads to continue receiving mini-boosters (n=150) or return to treatment as usual (n=150). Data collection at baseline, 12, and 18 months will include surveys and electronic medical record (EMR) data. The study will be implemented in community-based clinics and academic-affiliated health centers in Chicago and in Birmingham and Huntsville, Alabama. To study implementation in each setting and geographic context, we will use the Consolidated Framework for Implementation Research as the determinant framework and Reach, Effectiveness, Adoption, Implementation, and Maintenance as the evaluation framework. The specific aims of the study are to:

Aim 1: Evaluate the (a) effectiveness of a social support intervention versus treatment as usual over 12 months with 600 people living with HIV ages 18-49 and (b) value of continuing to offer social support over another 6 months. The primary outcomes are retention in care and Viral Suppression, as measured by electronic medical record data on missed visit proportion and viral load.

Aim 2: Examine if intervention effects (a) vary between Chicago and Alabama, (b) are mediated by changes in the Index's level of motivational readiness, self-efficacy, and stigma expectancies, and (c) are moderated by mental health and substance use at the Index level.

Aim 3: Evaluate the implementation of the intervention using the Consolidated Framework for Implementation Research and the Reach, Evaluation, Adoption, Implementation and Maintenance frameworks. We will conduct surveys and focus groups with key stakeholders to assess the inner and outer settings, implementer and intervention characteristics, and multi-level process factors within the Consolidated Framework for Implementation Research. We will assess the following implementation outcomes for the study in each clinical setting and geographic context: Reach, Adoption, Implementation, and Maintenance.

If effective, the intervention has the potential to reduce HIV incidence by harnessing existing social support in the lives of people living with HIV, strengthening the public health impact of Treatment as Prevention. Thus, the research holds significant promise for addressing racial and geographic health disparities and will result in a sustainable, scalable program and implementation strategy that can be disseminated in HIV clinics nationwide.

02

Conditions studied

  • HIV Seropositivity

Browse trials for

Keywords

  • HIV care engagement
  • HIV viral suppression
  • Social support
  • Social networks
03

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Index Participants:

  • Aged 18-49 years old, inclusive
  • Speak English
  • Own a cell phone not shared with anyone else
  • Have missed at least one HIV care scheduled visit or have not been virally suppressed in the past 24 months.
  • Resides in Chicagoland, Illinois or Alabama

Exclusion Criteria for Index Men:

  • If a participant fails to meet all inclusion criteria

Inclusion Criteria for Support Confidants:

  • Index agrees to engage the Support Confidant
  • Age 18 years or older
  • Speaks English
  • Owns a cell phone not shared with others
  • Is not a romantic/sexual partner of the Index participant

Exclusion Criteria:

  • Romantic/Sexual partners of Index participant
  • Relationship strain or abuse present in Index-Support Confidant relationship
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Social Network Support Intervention Condition

    The intervention condition will be delivered by trained Intervention Case Managers to n=300 Index participants and their Support Confidant. The intervention consists of (1) selection and invitation of a Support Confidant, (2) a face-to-face intervention between the Intervention Case Manager and the Index and Support Confidant, and (3) quarterly interactive mini-booster sessions delivered to the Index and Support Confidant via text or telephone, based on participant preference. At 12 months, Index participants in the experimental condition will be re-randomized to either continue receiving quarterly interactive mini-booster sessions or to stop receiving mini-boosters and return to treatment as usual.

    Behavioral: Social Network Support Intervention

  • No intervention
    Treatment as Usual Condition

    Treatment as Usual is comprehensive and follows Department of Health and Human Services guidelines and local protocols on the provision of HIV primary care, which include scheduling one HIV primary care visit and lab tests (including viral load) once every six months, i.e., two HIV primary care visits per year. In addition, all sites provide standard case management and mental health and psychosocial support services to all patients.

Interventions

  • BehavioralSocial Network Support Intervention

    The Social Network Support Intervention is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV. The intervention consists of (1) selection and invitation of a Support Confidant, (2) a face-to-face intervention between the Intervention Case Manager and the Index and Support Confidant, and (3) quarterly interactive mini-booster sessions delivered to the Index and Support Confidant via text or telephone, based on participant preference.

05

What researchers measure

Primary outcomes

  1. Missed Visit Proportion

    We count visits as scheduled (non-acute) visits to an antiretroviral prescribing provider. Missed Visit Proportion (MVP) is calculated as the proportion of total scheduled visits that are missed during the follow-up period. To permit longitudinal analyses, we shall also split the two-year follow-up period into eight three-month quarters and record, for each participant, whether he completed or missed his scheduled appointment during that quarter. Appointment and visit history to calculate MVP will be collected from each clinic's electronic medical record data.

    Time frame: 18 months

  2. Viral Suppression

    Viral load (suppressed or not) will be measured in RNA copies/mL, with ≤200 copies/mL defined as viral suppression.

    Time frame: 18 months

06

Study locations

4 of 7 sites recruiting
  • University of Alabama at Birmingham 1917 Clinic
    Birmingham, Alabama 35205, United States
    • Kathy Gaddis · Contact · kgaddis@uabmc.edu
    • Kathy Gaddis, MSW · Principal investigator
    Not yet recruiting
  • Birmingham AIDS Outreach
    Birmingham, Alabama 35233, United States
    • Emma S Kay, PhD · Contact · emma@mcwc-bao.org
    • Emma S Kay, PhD · Principal investigator
    Recruiting
  • Thrive Alabama
    Huntsville, Alabama 65801, United States
    Recruiting
  • Howard Brown Health
    Chicago, Illinois 60613, United States
    Recruiting
  • Chicago Center for HIV Elimination
    Chicago, Illinois 60637, United States
    Recruiting
  • Crown Family School of Social Work, Policy, and Practice at the University of Chicago
    Chicago, Illinois 60637, United States
    Not yet recruiting
  • Tulane University
    New Orleans, Louisiana 70118, United States
    • David S Batey, PhD · Contact · dsbatey@tulane.edu
    • David S Batey, PhD · Principal investigator
    Not yet recruiting
07

References and documents

Publications

  • Bouris A, Jaffe K, Eavou R, Liao C, Kuhns L, Voisin D, Schneider JA. Project nGage: Results of a Randomized Controlled Trial of a Dyadic Network Support Intervention to Retain Young Black Men Who Have Sex With Men in HIV Care. AIDS Behav. 2017 Dec;21(12):3618-3629. doi: 10.1007/s10461-017-1954-8. PubMed 29079949 ↗
  • Bouris A, Voisin D, Pilloton M, Flatt N, Eavou R, Hampton K, Kuhns LM, Eder M, Schneider JA. Project nGage: Network Supported HIV Care Engagement for Younger Black Men Who Have Sex with Men and Transgender Persons. J AIDS Clin Res. 2013 Aug 31;4:10.4172/2155-6113.1000236. doi: 10.4172/2155-6113.1000236. PubMed 24404408 ↗
  • Cabral HJ, Tobias C, Rajabiun S, Sohler N, Cunningham C, Wong M, Cunningham W. Outreach program contacts: do they increase the likelihood of engagement and retention in HIV primary care for hard-to-reach patients? AIDS Patient Care STDS. 2007;21 Suppl 1:S59-67. doi: 10.1089/apc.2007.9986. PubMed 17563291 ↗
  • Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010-2015. HIV Surveillance Supplemental Report 2018;23(No. 1). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published March 2018. Accessed [1 Dec 2022].
  • Craw JA, Gardner LI, Marks G, Rapp RC, Bosshart J, Duffus WA, Rossman A, Coughlin SL, Gruber D, Safford LA, Overton J, Schmitt K. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):597-606. doi: 10.1097/QAI.0b013e3181684c51. PubMed 18285714 ↗
  • Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812. PubMed 22310560 ↗
  • Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. doi: 10.1186/1748-5908-4-50. PubMed 19664226 ↗
  • Department of Health and Human Services. Ending the HIV Epidemic: A Plan for America. 2019; https://www.hhs.gov/sites/default/files/ending-the-hiv-epidemic-fact-sheet.pdf.
  • Diggle P, Liang K, Zeger S. Analysis of Longitudinal Data: Oxford Statistical Science Series. 1994.
  • Eisinger RW, Dieffenbach CW, Fauci AS. HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA. 2019 Feb 5;321(5):451-452. doi: 10.1001/jama.2018.21167. No abstract available. PubMed 30629090 ↗
  • Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic: A Plan for the United States. JAMA. 2019 Mar 5;321(9):844-845. doi: 10.1001/jama.2019.1343. No abstract available. PubMed 30730529 ↗
  • Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006 Jul;25(4):462-73. doi: 10.1037/0278-6133.25.4.462. PubMed 16846321 ↗
  • Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Vol 998: John Wiley & Sons; 2012.
  • Garamszegi LZ. Comparing effect sizes across variables: generalization without the need for Bonferroni correction. Behavioral Ecology. 2006;17(4):682-687.
  • Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999 Sep;89(9):1322-7. doi: 10.2105/ajph.89.9.1322. PubMed 10474547 ↗
  • Higa DH, Marks G, Crepaz N, Liau A, Lyles CM. Interventions to improve retention in HIV primary care: a systematic review of U.S. studies. Curr HIV/AIDS Rep. 2012 Dec;9(4):313-25. doi: 10.1007/s11904-012-0136-6. PubMed 22996171 ↗
  • Hogan B, Carrasco JA, Wellman B. Visualizing Personal Networks: Working with Participant-aided Sociograms. Field Methods. 2007;19(2):116-144.
  • Hoots BE, Finlayson TJ, Wejnert C, Paz-Bailey G; National HIV Behavioral Surveillance (NHBS) Study Group. Updated Data on Linkage to Human Immunodeficiency Virus Care and Antiretroviral Treatment Among Men Who Have Sex With Men-20 Cities, United States. J Infect Dis. 2017 Oct 17;216(7):808-812. doi: 10.1093/infdis/jix007. PubMed 28368493 ↗
  • Jiang H, Kulkarni PM, Mallinckrodt CH, Shurzinske L, Molenberghs G, Lipkovich I. Covariate Adjustment for Logistic Regression Analysis of Binary Clinical Trial Data. Statistics in Biopharmaceutical Research. 2017;9(1):126-134.
  • Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13-22.
  • McCullagh P, Nelder J. Generalized linear models., 2nd edn.(Chapman and Hall: London). Standard book on generalized linear models. 1989.
  • Naar-King S, Templin T, Wright K, Frey M, Parsons JT, Lam P. Psychosocial factors and medication adherence in HIV-positive youth. AIDS Patient Care STDS. 2006 Jan;20(1):44-7. doi: 10.1089/apc.2006.20.44. PubMed 16426155 ↗
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
  • Starace F, Massa A, Amico KR, Fisher JD. Adherence to antiretroviral therapy: an empirical test of the information-motivation-behavioral skills model. Health Psychol. 2006 Mar;25(2):153-62. doi: 10.1037/0278-6133.25.2.153. PubMed 16569106 ↗
  • Valeri L, Vanderweele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods. 2013 Jun;18(2):137-50. doi: 10.1037/a0031034. Epub 2013 Feb 4. PubMed 23379553 ↗
  • VanderWeele TJ, Vansteelandt S. Mediation Analysis with Multiple Mediators. Epidemiol Methods. 2014 Jan;2(1):95-115. doi: 10.1515/em-2012-0010. PubMed 25580377 ↗
  • VanderWeele TJ, Tchetgen Tchetgen EJ. Mediation analysis with time varying exposures and mediators. J R Stat Soc Series B Stat Methodol. 2017 Jun;79(3):917-938. doi: 10.1111/rssb.12194. Epub 2016 Jun 27. PubMed 28824285 ↗
  • Vittinghoff E, Sen S, McCulloch CE. Sample size calculations for evaluating mediation. Stat Med. 2009 Feb 15;28(4):541-57. doi: 10.1002/sim.3491. PubMed 19065627 ↗
  • White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011 Feb 20;30(4):377-99. doi: 10.1002/sim.4067. Epub 2010 Nov 30. PubMed 21225900 ↗

Study documents

  • Statistical analysis plan · Jan 30, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Individual Participant Data (IPD) will not be available to researchers outside of the study team.

08

Registry details

Key details

Study ID
NCT05723653
Lead sponsor
University of Chicago
Collaborators
Tulane University, University of Alabama at Birmingham, Birmingham AIDS Outreach, Chicago Center for HIV Elimination, Howard Brown Health, Thrive Alabama
Responsible party
Sponsor
First posted
Feb 13, 2023
Start date
Feb 13, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 8, 2026

Study contacts

Alida Bouris, PhD
Contact
abouris@uchicago.edu
773-834-4304
David S Batey, PhD
Contact
dsbatey@tulane.edu
504-862-3485
Alida Bouris, PhD
principal investigator · University of Chicago
David S Batey, PhD
principal investigator · Tulane University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion